



Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer

OSLO, Norway, 18 August 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced the appointment of Timothy F. Herpin, Ph.D., M.B.A., as Chief Business Officer. Herpin will serve on a fractional basis effective 17 August 2026.

The appointment strengthens the Company’s global business development and partnering capabilities as Lytix advances its clinical programs and seeks strategic partnerships across its portfolio.

Herpin brings more than 25 years of experience in pharmaceutical and biotechnology business development, spanning licensing, co-development and co-commercialization partnerships, mergers and acquisitions, and portfolio strategy across oncology and other therapeutic areas.

“We are in an important phase for Lytix as we advance ruxotemitide and build the partnerships required to realize the full value of our portfolio,” said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. “Tim brings extensive transaction experience, a strong international network and a deep understanding of how to position innovative oncology assets for potential partners. His appointment strengthens our ability to move partnering discussions from initial engagement through diligence, negotiation and execution.”

As Chief Business Officer, Herpin will lead Lytix’s global business development and partnering activities. Working closely with the CEO, management team and Board of Directors, he will develop and execute the Company’s partnering strategy.

Prior to joining Lytix, Herpin founded Anza Advisors, where he provides fractional Chief Business Officer services to biotechnology companies. He previously served as Chief Business Officer of Santa Ana Bio, where he led business development, contributing to raise a \$125 million Series B financing, and of Caribou Biosciences, where he helped shape the company’s strategy for a portfolio of allogeneic CAR-T cell therapies. He also spent five years as Vice President and Head of Transactions, Business Development at AstraZeneca, leading licensing, M&A and partnering transactions across oncology and other disease areas. During his career, Herpin also held senior business development roles at Johnson & Johnson and Bristol Myers Squibb.

“I am pleased to join Lytix at this point in the Company’s development,” said Herpin. “Lytix has built a differentiated immuno-oncology portfolio supported by encouraging clinical and scientific evidence. I look forward to working with the team to strengthen the Company’s partnering strategy, engage relevant global companies and advance discussions toward value-creating transactions.”

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX. For more information, visit www.lytixbiopharma.com.